Photon Fund
VC Fund
Shenzhen, China
Photon Fund is a venture capital institution concentrating on technology and innovation. Strategically located in Shenzhen, with office in Beijing and Silicon Valley, which are the most creative cities, Photon Fund invests in global scale. The core team consists of members with over 20 years of experience in equity investment in wellknowninstitutions globally. They have rich experience and industry resources in TMT and high-end manufacturing fields. They are a research-based investment institution, persisting in their independent judgment to seek for the truth behind the event. Meanwhile the team holds value investment and industrial investment as the core philosophy and creates value for the invested enterprises continuously. Photon Fund is playing an important role in promoting scientific and technological progress and innovation in China.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Photon Fund invests in
Stages Photon Fund invests in
Countries Photon Fund invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
David Wang
|
|||
James Lee
|
|||
Qing Zhu
|
|||
Investment Focus
Industry
- Biotechnology 4 (33%)
- Medical 3 (25%)
- Therapeutics 3 (25%)
- Health Care 2 (17%)
- Broadcasting 2 (17%)
Stage
- Series A 4 (33%)
- Series B 4 (33%)
- Series C 2 (17%)
- Seed 1 (8%)
Country
- China 5 (42%)
- United States 5 (42%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
David Wang
Founding General Partner
|
Founding General Partner | Total investments: 0 | Find email | |
|
James Lee
Associate Director
|
Associate Director | Total investments: 0 | Find email | |
|
Qing Zhu
Founding General Partner
|
Founding General Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Bichen Pharmaceutical
|
Bichen Pharmaceutical is a small-molecule tumor-targeted drug developer for the treatment of various malignant tumors and brain metastases. | $30M / Series B / Jan 04, 2022 | |
Amplicore
|
Amplicore develops injectable and minimally invasive therapeutics for musculoskeletal disorders. | $4M / Seed / Mar 25, 2021 | |
Newomics
|
Newomics is an early stage biotechnology company that commercializes innovative and integrative platforms and solutions for personalized healthcare. Its proprietary technology is based on silicon-microfluidic-chip for liquid chromatography-mass spectrometry (LC-MS) and offers unprecedented robustness, sensitivity, specificity, and throughput foranalyzing molecules from minute amounts of biospecimens such as blood and urine. | $7.9M / Series B / Dec 01, 2020 | |
Cardea Bio
|
Cardea is developing a new generation of (bio)technology infrastructure based on proprietary biology-gated transistors. Cardean transistors leverage biocompatible graphene instead of silicon and replace optical signal observations with direct electrical molecular signal analysis. With Cardean transistors, the company and its Innovation Partners cangenerate streaming multi-omics data to measure real-time biological signals. Cardea is now manufacturing chips at scale and partners have started to significantly expand the amount, type, and quality of biological data they capture by building products that Conduct Biolog. | $7.5M / Series A / Sep 17, 2020 | |
Nelumbo
|
Nelumbo is commercializing a new platform of structural materials. The company’s current focus is on developing improved heat exchangers for the HVAC market. Our ability to improve energy performance and minimize corrosion in a single platform unlocks mass market opportunity with potential for significant carbon emission and energy use reductionsworldwide. | $14M / Series A / Apr 15, 2020 | |
Valitor
|
Valitor, Inc. has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacokinetics, target specificity and bioactivity. Their technology platform can be broadly applied to improve the pharmacological properties of many protein drugs that are currently approved or under development. They currentlyhave three development pipelines in the fields of dermatology, ophthalmology, and orthopedics that highlight the capabilities of their novel drug products. | $2.5M / Series A / Sep 20, 2018 | |
|
Newomics
|
Newomics is an early stage biotechnology company that commercializes innovative and integrative platforms and solutions for personalized healthcare. Its proprietary technology is based on silicon-microfluidic-chip for liquid chromatography-mass spectrometry (LC-MS) and offers unprecedented robustness, sensitivity, specificity, and throughput foranalyzing molecules from minute amounts of biospecimens such as blood and urine. | $3.9M / Series A / Aug 09, 2018 | |
|
Nelumbo
|
Nelumbo is commercializing a new platform of structural materials. The company’s current focus is on developing improved heat exchangers for the HVAC market. Our ability to improve energy performance and minimize corrosion in a single platform unlocks mass market opportunity with potential for significant carbon emission and energy use reductionsworldwide. | $5.5M / Series A / Jul 27, 2018 | |
CARsgen Therapeutics
|
CARsgen is a leading clinical-stage immunotherapy company focused on the development of new chimeric antigen receptor T (CAR-T) cell therapeutics for liver, lung, stomach and brain cancers. The company has partnership with Shanghai Cancer Institute and Shanghai Renji Hospital. The company is leading the first tier of CAR-T development, bycompleting World’s first hepatocellular carcinoma (HCC) and China’s exclusive glioblastoma multiforme (GBM) dose ascending injection tests. Funded by leading venture capital firm BVCF, CARsgen is well-positioned to bring a novel cancer therapeutics to the market in China and worldwide. | $60M / Series C / Mar 02, 2018 | |
Hongliyu Cinema
|
Hongliyu Cinema is a Chinese rural cinema operator. It focuses on film and television production and advertising operation services, and professional support in China. | $15M / Series B / Jan 08, 2018 | |
| See all 12 investments → | |||
Co-Investors
Berkeley Catalyst Fund (BCF)
6 deals together
Danfoss Ventures
2 deals together
Skylight Investment
2 deals together
1517 Fund
1 deal together
Agilent Technologies
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Photon Fund invest in?
Photon Fund invests primarily in Biotechnology, Medical and Therapeutics startups, most often at Series A and Series B stage. Most of the 12 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Photon Fund?
Public channels for Photon Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Photon Fund?
The team at Photon Fund includes David Wang (Founding General Partner), James Lee (Associate Director) and Qing Zhu (Founding General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
